Search | Clinical Trials Finder

Conditions: Prostate Cancer
Interventions: stereotactic ablative radiotherapy, Pluvicto, topical testosterone; Radiation · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: West Los Angeles, California • Hines, Illinois • Indianapolis, Indiana + 1 more

Conditions: Neuroendocrine Tumors
Interventions: 177Lu-DOTA-EB-TATE, Amino Acid Solution; Drug · Other
Lead sponsor: Molecular Targeting Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: AAA617; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 24
States / cities: Scottsdale, Arizona • Orange, California • Santa Monica, California + 19 more

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: AAA617, Gonadotropin-releasing hormone (GnRH) analogues, Gonadotropin-releasing hormone (GnRH) antagonists; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • Palo Alto, California • Rochester, Minnesota + 2 more

Conditions: Non-hodgkin Lymphoma
Interventions: CD38-SADA:177Lu-DOTA Complex; Drug
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 6
States / cities: Scottsdale, Arizona • Duarte, California • Grand Rapids, Michigan + 3 more

Conditions: Metastatic Nonsmall Cell Lung Cancer
Interventions: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Metastatic Cancer
Interventions: [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Inoperable Solid Tumors or Lymphomas
Interventions: AvidinOX, 177Lu-ST2210; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions: AAA617, ARPI: Abiraterone, ARPI: Enzalutamide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more

Conditions: Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
Interventions: Pasritamig, Cetrelimab, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP), Lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 7
States / cities: Sarasota, Florida • Grand Rapids, Michigan • St Louis, Missouri + 4 more

Conditions: Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Esophageal Cancer, Gliomas
Interventions: 177Lu-J591; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostatic Neoplasms
Interventions: 177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 1,140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 70
States / cities: Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more

Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions: recombinant interferon alfa, chemotherapy, paclitaxel, topotecan hydrochloride, lutetium Lu 177 monoclonal antibody CC49, yttrium Y 90 monoclonal antibody CC49; Biological · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1996
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: [177Lu]Ludotadipep 3.7 GBq; Drug
Lead sponsor: FutureChem; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Towson, Maryland + 1 more

Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Lutetium Lu-177 PNT2002, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy; Drug · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions: Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Flotufolastat F-18, Lutetium Lu 177 PSMA-10.1, Positron Emission Tomography, Single Photon Emission Computed Tomography; Procedure · Radiation · Other + 1 more
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions: 177Lu-DOTATOC; Drug
Lead sponsor: Excel Diagnostics and Nuclear Oncology Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor
Interventions: Single Photon Emission Computed Tomography/ Computed Tomography (SPECT/CT), Photon Emission Tomography / CT (PET/CT), 64Cu-Dotatate, 177Lu-Dotatate; Device · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: XL092; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: 177Lu-PSMA-617; Drug
Lead sponsor: Endocyte; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Houston, Texas

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors
Interventions: Lutathera, Azedra; Drug
Lead sponsor: David Bushnell; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Relapsed / Refractory Osteosarcoma
Interventions: LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).; Drug
Lead sponsor: Lantheus Medical Imaging; Industry
Eligibility: 12 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Prostate Cancer
Interventions: Investigators choice of SoC, AAA817; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 27
States / cities: Los Angeles, California • Palo Alto, California • Santa Barbara, California + 22 more

Search by objective public record fields.

Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc

177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

Phase 1, Open-label, Dose-escalation Trial With CD38-SADA:177 Lu-DOTA Drug Complex in Subjects With Relapsed or Refractory Non-Hodgkin Lymphoma

Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Radiolabeled Monoclonal Antibody, Paclitaxel, and Interferon Alfa in Treating Patients With Recurrent Ovarian Cancer

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

Using Novel Imaging to More Safely Treat Neuroendocrine Tumors

XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors

Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy